Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).

MLA

Sakai, Daisuke, et al. “Randomised Phase II Study of Panitumumab plus Irinotecan versus Cetuximab plus Irinotecan in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G).” European Journal of Cancer (Oxford, England : 1990), vol. 135, Aug. 2020, pp. 11–21. EBSCOhost, https://doi.org/10.1016/j.ejca.2020.04.014.

APA

Sakai, D., Taniguchi, H., Sugimoto, N., Tamura, T., Nishina, T., Hara, H., Esaki, T., Denda, T., Sakamoto, T., Okuda, H., Satoh, T., Tsushima, T., Makiyama, A., Tsuda, T., Hosokawa, A., Kuramochi, H., Tokunaga, S., Moriwaki, T., Yasui, H., … Muro, K. (2020). Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). European Journal of Cancer (Oxford, England : 1990), 135, 11–21. https://doi.org/10.1016/j.ejca.2020.04.014

Chicago

Sakai, Daisuke, Hiroya Taniguchi, Naotoshi Sugimoto, Takao Tamura, Tomohiro Nishina, Hiroki Hara, Taito Esaki, et al. 2020. “Randomised Phase II Study of Panitumumab plus Irinotecan versus Cetuximab plus Irinotecan in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G).” European Journal of Cancer (Oxford, England : 1990) 135 (August): 11–21. doi:10.1016/j.ejca.2020.04.014.